
**CLAIMS**

1. A compound according to formula (I)



(I)

wherein

$R_1$ is selected from the group consisting of 5-or 6-membered heteroaryl, 9- or 10-membered bicyclic heteroaryl, phenyl, $(C_1\text{-}C_6)$alkoxy, $(C_3\text{-}C_7)$cycloalkoxy, $(C_1\text{-}C_6)$alkyl, phenyl-$(C_1\text{-}C_4)$alkyl, $(C_3\text{-}C_7)$cycloalkyl, 4-6-membered heterocycloalkyl and $-NR_cR_d$, wherein said 5-or 6-membered heteroaryl, 9- or 10-membered bicyclic heteroaryl, phenyl, $(C_1\text{-}C_6)$alkoxy, $(C_3\text{-}C_7)$cycloalkoxy, $(C_1\text{-}C_6)$alkyl, phenyl-$(C_1\text{-}C_4)$alkyl, $(C_3\text{-}C_7)$cycloalkyl and 4-6-membered heterocycloalkyl is optionally substituted with one or more substituents independently selected from $R_a$;

$R_a$ represents deuterium, halogen, hydroxy, $-NR_cR_d$, $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkylcarbonyl, $(C_3\text{-}C_7)$cycloalkyl, phenyl,5- or 6-membered heteroaryl or 4-6-membered heterocycloalkyl, wherein said $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkylcarbonyl, $(C_3\text{-}C_7)$cycloalkyl, phenyl, 5- or 6-membered heteroaryl or 4-6-membered heterocycloalkyl is optionally substituted with one or more substituents independently selected from deuterium, halogen, hydroxy, cyano, $(C_1\text{-}C_4)$alkyl, $(C_3\text{-}C_7)$cycloalkyl, $(C_1\text{-}C_4)$alkoxy, $-SO_2\text{-}(C_1\text{-}C_4)$alkyl and $-NR_cR_d$;

$R_2$ is selected from the group consisting of 5- or 6-membered heteroaryl, wherein said 5- or 6-membered heteroaryl is optionally substituted with one or more substituents independently selected from $R_b$, wherein said 5- or 6-membered heteroaryl may optionally contain -CO- as a ring member and wherein when said 5 membered heteroaryl contains nitrogen as a ring atom said nitrogen may optionally be substituted with a substituent selected from $R_8$;

$R_b$ represents deuterium, halogen, cyano, hydroxy, $-NR_cR_d$ , $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, $(C_1\text{-}C_6)$alkyl-CO-O-$(CH_2)_n$- or $(C_3\text{-}C_7)$cycloalkyl, wherein n is 1-4, and wherein said $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy or $(C_3\text{-}C_7)$cycloalkyl is optionally substituted with one or more

substituents independently selected from deuterium, halogen, cyano, hydroxy, $-NR_cR_d$ and $(C_1\text{-}C_4)$alkoxy;

$R_c$ and $R_d$ each independently are selected from the group consisting of hydrogen and $(C_1\text{-}C_6)$alkyl, or $R_c$ and $R_d$ together form pyrrolidinyl or piperidinyl, wherein said $(C_1\text{-}C_6)$alkyl, pyrrolidinyl or piperidinyl is optionally substituted with one or more substituents independently selected from halogen, cyano and hydroxy;

$R_8$ is selected from the group consisting of $-L\text{-}PO(OH)_2$ and $-CHR_gO\text{-}(CO\text{-}A\text{-}NR_h)_m\text{-}CO\text{-}A\text{-}NR_hR_i$,

L is selected from the group consisting of a bond or $-CHR_gO-$,

m is 0 or 1;

wherein each $-CO\text{-}A\text{-}NR_h-$ independently represent an amino acid residue wherein the amino acid residue is selected from the natural amino acids either in D or L-form or as mixtures of the D and L form, and wherein said amino acid residue may be substituted on the α-amino group with a substituent $R_h$;

$R_g$, $R_h$, and $R_i$ are independently selected from hydrogen and $(C_1\text{-}C_6)$alkyl;


$R_3$ is selected from the group consisting of hydrogen, deuterium, hydroxy and halogen;

$R_4$ is selected from the group consisting of hydrogen, deuterium and halogen;

$R_5$ is $-CHR_6R_7$, and wherein $R_6$ and $R_7$ each independently represents $(C_3\text{-}C_7)$cycloalkyl, wherein said $(C_3\text{-}C_7)$cycloalkyl is optionally substituted with one or more substituents independently selected from halogen, cyano, hydroxy and $(C_1\text{-}C_4)$alkyl;

or pharmaceutically acceptable salts thereof.

2. The compound according to claim 1 having the general formula (Ia)




(Ia)

wherein the substituents are as defined in in claim 1, or pharmaceutically acceptable salts thereof.

3. The compound according to any of claims 1-2, wherein $R_1$ is selected from 5-membered heteroaryl, 9-membered bicyclic heteroaryl, ($C_3$-$C_7$)cycloalkyl, 4-6-membered heterocycloalkyl, ($C_1$-$C_6$)alkyl and ($C_1$-$C_6$)alkoxy, wherein said 5-membered heteroaryl, 9-membered bicyclic heteroaryl, ($C_3$-$C_7$)cycloalkyl, 4-6-membered heterocycloalkyl, ($C_1$-$C_6$)alkyl and ($C_1$-$C_6$)alkoxy is optionally substituted with one or more substituents independently selected from $R_a$.

4. The compound according to any of claims 1-3, wherein $R_2$ is selected from the group consisting of 5-membered heteroaryl, wherein the 5- membered heteroaryl is optionally substituted with one or more substituents independently selected from $R_b$.

5. The compound according to any of claims 1-3, wherein $R_2$ is selected from the group consisting of 5-membered heteroaryl, wherein said 5- membered heteroaryl contain a nitrogen ring atom substituted by a substituent selected from $R_8$ and the other ring atoms of said 5-membered heteroaryl is optionally substituted with one or more substituents independently selected from $R_b$.

6. The compound according to claim 4 wherein $R_2$ is selected from pyrazolyl and imidazolyl, wherein said pyrazolyl or imidazolyl is optionally substituted with one or more substituents independently selected from $R_b$.

7. The compound according to claim 6 wherein $R_2$ is pyrazol-4-yl or imidazole-4-yl, wherein said pyrazol-4-yl or imidazol-4-yl is optionally substituted with one or more substituents independently selected from ($C_1$-$C_6$)alkyl.

8. The compound according to claim 5 wherein $R_2$ is selected from pyrazolyl and imidazolyl, wherein said pyrazolyl or imidazolyl contain a nitrogen ring atom substituted by a substituent selected from $R_8$ and the other ring atoms of said 5-membered heteroaryl is optionally substituted with one or more substituents independently selected from $R_b$.

9. The compound according to claim 8 wherein $R_2$ is selected from pyrazol-4-yl or imidazole-4-yl, wherein said pyrazol-4-yl or imidazol-4-yl contain a nitrogen ring atom substituted by a substituent selected from $R_8$ and the other ring atoms of said pyrazol-4-yl or imidazole-4-yl is optionally substituted with one or more substituents independently selected from $(C_1\text{-}C_6)$alkyl.

10. The compound according to any one of claims 1-3, 5 and 8-9 wherein $R_8$ is selected from the group consisting of

$\text{-L-PO(OH)}_2$ and $\text{-CHR}_g\text{O-(CO-A-NR}_h\text{)}_m\text{-CO-A-NR}_h\text{R}_i$,

wherein L is selected from the group consisting of a bond or $\text{-CHR}_g\text{O-}$,

m is 0 or 1 and $\text{-CO-A-NR}_h\text{-}$ represents an amino acid residue selected from

$\text{-CO-CH}_2\text{-NR}_h\text{-}$,
$\text{-CO-CH(CH}_3\text{)-NR}_h\text{-}$,
$\text{-CO-CH(CH}_2\text{OH)-NR}_h\text{-}$,
$\text{-CO-CH(CH}_2\text{SH)-NR}_h\text{-}$,
$\text{-CO-CH(CH(CH}_3\text{)(OH))-NR}_h\text{-}$,
$\text{-CO-CH(CH(CH}_3\text{)}_2\text{)-NR}_h\text{-}$,
$\text{-CO-CH(CH}_2\text{CH(CH}_3\text{)}_2\text{)-NR}_h\text{-}$,
$\text{-CO-CH(CH(CH}_3\text{)(CH}_2\text{CH}_3\text{))-NR}_h\text{-}$,
$\text{-CO-CH(CH}_2\text{CH}_2\text{-S-CH}_3\text{)-NR}_h\text{-}$ ,
$\text{-CO-CH(CH}_2\text{-phenyl)-NR}_h\text{-}$,
$\text{-CO-CH(CH}_2\text{(4-hydroxyphenyl)-NR}_h\text{-}$,
$\text{-CO-CH(CH}_2\text{-COOH)-NR}_h\text{-}$,
$\text{-CO-CH(CH}_2\text{-CH}_2\text{-COOH)-NR}_h\text{-}$,
$\text{-CO-CH(CH}_2\text{-CH}_2\text{-CONH}_2\text{)-NR}_h\text{-}$,
$\text{-CO-CH(CH}_2\text{-CONH}_2\text{)-NR}_h\text{-}$,
$\text{-CO-CH((CH}_2\text{)}_4\text{ –NH}_2\text{)-NR}_h\text{-}$,
$\text{-CO-CH((CH}_2\text{)}_3\text{ –NH-C(NH)(NH}_2\text{))-NR}_h\text{-}$,

-CO-CH-($CH_2$ –(4-imidazolyl))-$NR_h$- and
-CO-CH-($CH_2$ –(3-indolyl))-$NR_h$.

and $R_g$, $R_h$, and $R_i$ are independently selected from hydrogen and ($C_1$-$C_6$)alkyl.

11. The compound according to any of claims 1-3, 5 and 8-9 wherein $R_8$ is -$CH_2$-$PO(OH)_2$.

12. A compound according to claim 1 selected from
N-[(1S)-1-(dicyclopropylmethyl)-2-[4-(3,5-dimethyl-1H-pyrazol-4-yl)anilino]-2-oxo-ethyl]-2-isopropyl-pyrazole-3-carboxamide,
N-[(1S)-1-(dicyclopropylmethyl)-2-[4-(3,5-dimethyl-1H-pyrazol-4-yl)anilino]-2-oxo-ethyl]-2-ethyl-pyrazole-3-carboxamide,
N-[(1S)-1-(Dicyclopropylmethyl)-2-[4-(3,5-dimethyl-1H-pyrazol-4-yl)anilino]-2-oxo-ethyl]-2-[(1S)-2-hydroxy-1-methyl-ethyl]pyrazole-3-carboxamide,
N-[(1S)-1-(dicyclopropylmethyl)-2-[4-(3,5-dimethyl-1H-pyrazol-4-yl)anilino]-2-oxo-ethyl]-2-(3-hydroxypropyl)pyrazole-3-carboxamide,
N-[(1S)-1-(dicyclopropylmethyl)-2-[4-(3,5-dimethyl-1H-pyrazol-4-yl)anilino]-2-oxo-ethyl]-2-propyl-pyrazole-3-carboxamide,
N-[(1S)-1-(dicyclopropylmethyl)-2-[4-(3,5-dimethyl-1H-pyrazol-4-yl)-3-fluoro-anilino]-2-oxo-ethyl]-2-isopropyl-pyrazole-3-carboxamide,
N-[(1S)-1-(dicyclopropylmethyl)-2-[4-(3,5-dimethyl-1H-pyrazol-4-yl)-3-fluoro-anilino]-2-oxo-ethyl]-2-ethyl-pyrazole-3-carboxamide,
N-[(1S)-1-(dicyclopropylmethyl)-2-[4-(3,5-dimethyl-1H-pyrazol-4-yl)-3-fluoro-anilino]-2-oxo-ethyl]-2-[(1S)-2-hydroxy-1-methyl-ethyl]pyrazole-3-carboxamide,
N-[(1S)-1-(dicyclopropylmethyl)-2-[4-(3,5-dimethyl-1H-pyrazol-4-yl)anilino]-2-oxo-ethyl]-2-(4,4,4-trifluoro-3-hydroxy-butyl)pyrazole-3-carboxamide,
N-[(1S)-1-[di(cyclobutyl)methyl]-2-[4-(3,5-dimethyl-1H-pyrazol-4-yl)anilino]-2-oxo-ethyl]-2-(3-hydroxypropyl)pyrazole-3-carboxamide,
N-[(1S)-1-(Dicyclopropylmethyl)-2-[4-[5-(hydroxymethyl)-3-methyl-1H-pyrazol-4-yl]anilino]-2-oxo-ethyl]-2-isopropyl-pyrazole-3-carboxamide,
N-[(1S)-1-(Dicyclopropylmethyl)-2-[4-(3,5-dimethyl-1H-pyrazol-4-yl)-3-hydroxy-anilino]-2-oxo-ethyl]-2-isopropyl-pyrazole-3-carboxamide,
N-[(1S)-2,2-dicyclopropyl-1-[[4-(3-cyclopropyl-5-methyl-1H-pyrazol-4-yl)phenyl]carbamoyl]ethyl]-2-isopropyl-pyrazole-3-carboxamide,
N-[(1S)-1-(dicyclopropylmethyl)-2-[4-(3,5-diethyl-1H-pyrazol-4-yl)anilino]-2-oxo-ethyl]-2-[(1S)-2-hydroxy-1-methyl-ethyl]pyrazole-3-carboxamide, and

N-[(1S)-1-[di(cyclobutyl)methyl]-2-[4-(3,5-dimethyl-1H-pyrazol-4-yl)anilino]-2-oxo-ethyl]-2-(2-hydroxy-1-methyl-ethyl)pyrazole-3-carboxamide.

13. A compound according to claim 1 selected from
[4-[4-[[(2S)-3,3-dicyclopropyl-2-[(2-isopropylpyrazole-3-carbonyl)amino]propanoyl]amino]phenyl]-3,5-dimethyl-pyrazol-1-yl]methyl dihydrogen phosphate,
[4-[4-[[(2S)-3,3-dicyclopropyl-2-[(2-ethylpyrazole-3-carbonyl)amino]propanoyl]amino]phenyl]-3,5-dimethyl-pyrazol-1-yl]methyl dihydrogen phosphate,
[4-[4-[[(2S)-3,3-dicyclopropyl-2-[[2-(2-hydroxy-1-methyl-ethyl)pyrazole-3-carbonyl]amino]propanoyl]amino]phenyl]-3,5-dimethyl-pyrazol-1-yl]methyl dihydrogen phosphate and
[4-[4-[[(2S)-3,3-dicyclopropyl-2-[(2-isopropylpyrazole-3-carbonyl)amino]propanoyl]amino]phenyl]-3,5-dimethyl-pyrazol-1-yl]methyl (2S)-2-amino-3-methyl-butanoate
or pharmaceutically acceptable salts thereof.

14. A compound according to claim 1 selected from
Disodium [4-[4-[[(2S)-3,3-dicyclopropyl-2-[(2-isopropylpyrazole-3-carbonyl)amino]propanoyl]amino]phenyl]-3,5-dimethyl-pyrazol-1-yl]methyl phosphate disodium [4-[4-[[(2S)-3,3-dicyclopropyl-2-[(2-ethylpyrazole-3-carbonyl)amino]propanoyl]amino]phenyl]-3,5-dimethyl-pyrazol-1-yl]methyl phosphate, and disodium [4-[4-[[(2S)-3,3-dicyclopropyl-2-[[2-[(1S)-2-hydroxy-1-methyl-ethyl]pyrazole-3-carbonyl]amino]propanoyl]amino]phenyl]-3,5-dimethyl-pyrazol-1-yl]methyl phosphate.

15. A compound according to claim 1 selected from
N-[(1S)-1-(dicyclopropylmethyl)-2-[4-(3,5-dimethyl-1H-pyrazol-4-yl)anilino]-2-oxo-ethyl]-2-isopropyl-pyrazole-3-carboxamide, and pharmaceutically acceptable salts thereof.

16. A compound according to claim 1 which is
N-[(1S)-1-(dicyclopropylmethyl)-2-[4-(3,5-dimethyl-1H-pyrazol-4-yl)anilino]-2-oxo-ethyl]-2-isopropyl-pyrazole-3-carboxamide naphthalene-1,5-disulfonic acid salt.

17. A compound according to any one of claims 1-16 for use in therapy.

18. A compound according to claim 17 for use in treatment of autoimmune diseases.

19. A compound according to claim 17 for use in treatment of psoriasis, ankylosing spondylitis, spondyloarthritis or psoriatic arthritis.

20. A pharmaceutical composition comprising a compound according to any one of claims 1-16 together with a pharmaceutically acceptable vehicle or excipient or pharmaceutically acceptable carrier(s).

21. The pharmaceutical composition according to claim 20 together with one or more other therapeutically active compound(s).